Abstract: A document processing system processes a document image to identify document image regions including floating images, structured data units, and unstructured floating text. A first masked image is generated by deleting any floating images from the document image and a second masked image is generated by deleting any structured data units from the first masked image. The structured data units and the unstructured floating text are thus identified serially one after another. Textual data is extracted from the structured data units and the unstructured floating text by processing the corresponding document image regions via optical character recognition (OCR). Entities are extracted from the textual data using natural language processing (NLP) techniques.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: An example method for building a model to predict rare events is disclosed. The example disclosed herein comprises receiving a plurality of historical input logs wherein each log includes at least one key variable and unstructured data. The example further comprises applying text mining techniques to the unstructured data to obtain at least one predictor based on the unstructured data. The example further comprises creating a rare events prediction model based on the at least one key variable and the at least one predictor.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: Technology related to tools for supporting multi-language software programs is disclosed. In one example of the disclosed technology, a method can be used for testing a user interface of a software product. The method can include receiving a test recording captured using a first build of the software product targeted to a first language. A localized language file corresponding to a second language can be received. The test recording can be played back on a second build of the software product targeted to the second language. The playing back can include finding an equivalent under-test user interface element to a recorded user interface element of the test recording using a hierarchical search of properties in the localized language file. Additionally, the playing back can include performing a recorded action of the test recording on the equivalent under-test user interface element.

Abstract: An example method for building a model to predict rare events is disclosed. The example disclosed herein comprises receiving a plurality of historical input logs wherein each log includes at least one key variable and unstructured data. The example further comprises applying text mining techniques to the unstructured data to obtain at least one predictor based on the unstructured data. The example further comprises creating a rare events prediction model based on the at least one key variable and the at least one predictor.

Abstract: A system may include a therapy controller including a telemetry circuit configured to communicate with an implantable or wearable medical device and a processor configured to execute instructions relating to programming the implantable medical device, and a communication circuit operatively coupled to the therapy controller and configured to transfer information between the therapy controller and a remote device. The therapy controller is configured to receive at least one input relating to operation of the implantable medical device, convert the input into proposed programming instructions, apply device programming rules to verify the safety of the proposed programming instructions, and deliver the programming instructions to the implantable or wearable medical device. In an example, the therapy controller is also configured to deliver information about the programming and data from the IPG, such as various data reporting on the IPG status to a remote device using the communication circuit.

Abstract: Technology related to tools for supporting multi-language software programs is disclosed. In one example of the disclosed technology, a method can be used for testing a user interface of a software product. The method can include receiving a test recording captured using a first build of the software product targeted to a first language. A localized language file corresponding to a second language can be received. The test recording can be played back on a second build of the software product targeted to the second language. The playing back can include finding an equivalent under-test user interface element to a recorded user interface element of the test recording using a hierarchical search of properties in the localized language file. Additionally, the playing back can include performing a recorded action of the test recording on the equivalent under-test user interface element.

Abstract: Systems and methods are provided for identifying changes in a user interface between versions of an application, web page, or other product/service that includes the user interface. This can include matching changes in the visual appearance of the user interface with changes in the text strings presented in the user interface. Identifying user interfaces where the changes in the user interface image are matched with changes to the text associated with user interface objects in the user interface can allow improved identification of user interfaces that have changed.

Abstract: Described herein are various technologies pertaining to an adaptive recursive user interface testing automation framework. A workflow used to test a user interface of an application can be automatically adaptively modified. Updating of the workflow can disable testing of element(s) not included in the user interface (e.g., element(s) removed from the user interface), adding testing of element(s) included in the user interface (e.g., element(s) added to the user interface) and/or modifying testing of element(s) of the UI (e.g., element(s) modified in the user interface).

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: A system may include a therapy controller including a telemetry circuit configured to communicate with an implantable or wearable medical device and a processor configured to execute instructions relating to programming the implantable medical device, and a communication circuit operatively coupled to the therapy controller and configured to transfer information between the therapy controller and a remote device. The therapy controller is configured to receive at least one input relating to operation of the implantable medical device, convert the input into proposed programming instructions, apply device programming rules to verify the safety of the proposed programming instructions, and deliver the programming instructions to the implantable or wearable medical device. In an example, the therapy controller is also configured to deliver information about the programming and data from the IPG, such as various data reporting on the IPG status to a remote device using the communication circuit.

Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.

Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.

Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.

Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.